Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
87
-
Total 13F shares, excl. options
-
26M
-
Shares change
-
+3.73M
-
Total reported value, excl. options
-
$86.4M
-
Value change
-
+$11.9M
-
Put/Call ratio
-
2.15
-
Number of buys
-
44
-
Number of sells
-
-27
-
Price
-
$3.33
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q1 2021
108 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q1 2021.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 87 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26M shares
of 193M outstanding shares and own 13.42% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (5.98M shares), VANGUARD GROUP INC (2.83M shares), BlackRock Inc. (2.1M shares), Hudson Bay Capital Management LP (1.4M shares), ADVISOR GROUP HOLDINGS, INC. (1.37M shares), MORGAN STANLEY (1.13M shares), Point72 Asset Management, L.P. (1.04M shares), RENAISSANCE TECHNOLOGIES LLC (1M shares), TWO SIGMA INVESTMENTS, LP (769K shares), and CITADEL ADVISORS LLC (696K shares).
This table shows the top 87 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.